The U.S. Food and Drug Administration granted a 510(k) clearance for expanded indications of TransEnterix Inc.'s Senhance Surgical System.
The regulatory approval was granted for two surgeries namely, laparoscopic inguinal hernia, a tear in the abdominal muscle, and laparoscopic cholecystectomy, the removal of the gallbladder.
Following this approval, Senhance can be used for some of the most common abdominal surgeries, including procedures in general surgery and gynecology.
President and CEO Todd Pope said that the indication expansion doubles the addressable market for Senhance in the U.S.
